Search

Search Results

1. LAG-3 Inhibitors for the Treatment of Lung Cancer

   The immune checkpoint LAG-3 (lymphocyte activation gene 3) or CD223/FDC protein is located on chromosome 12 of the human genome. Enhancement of...

   Kaustubhi Sankpal, Saurabh Morparia, ... Manikanta Murahari in Immunotherapy Against Lung Cancer

   Chapter 2024
   

2. Immunotherapy for Cutaneous Melanoma

   Melanoma is the most aggressive skin cancer whose incidence is increasing in western countries. Among novel treatments, immunotherapy has shown...

   Alireza Soleymanitabar, Mahsa Keshavarz-Fathi, ... Nima Rezaei in Handbook of Cancer and Immunology

   Living reference work entry 2023
   

3. Current Approaches of Immune Checkpoint Therapy in Chronic Lymphocytic Leukemia

   Increasing understanding of the complex interaction between leukemic and immune cells, which is responsible for tumor progression and immune evasion,...

   Saeid Taghiloo, Hossein Asgarian-Omran in Current Treatment Options in Oncology

   Article 10 August 2023
   

4. Lag3: From Bench to Bedside

   The introduction of immune checkpoint inhibitors represented a breakthrough treatment for metastatic melanoma, but the effect of these agents is not...

   Francesca Aroldi, Reem Saleh, ... Mark R. Middleton in Cancer Immunotherapies

   Chapter 2022
   

5. Immune Checkpoint Inhibitors: Novel Therapies and Targets

   Immune checkpoint inhibitors (ICIs) are a relatively novel group of drugs that target and block specific molecules expressed on various types of...

   Elen Baloyan, Amalya Sargsyan, ... Samvel Bardakhchyan in

   Chapter 2024
   

6. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

   The discovery of immune checkpoint inhibitors (ICIs) has now been universally acknowledged as a significant breakthrough in tumor therapy after the...

   Yuchen Wang, Hao Zhang, ... Quan Cheng in Journal of Hematology & Oncology

   Article Open access 17 August 2022
   

7. Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2− negative breast cancer

   While checkpoint inhibitors have been approved in patients with newly metastatic PDL1-positive triple negative breast cancer, similar clinical...

   Matthew R. Kearney, Julia E. McGuinness, Kevin Kalinsky in Breast Cancer Research and Treatment

   Article 02 July 2021
   

8. Personalized Medicine in Clinical Management of Breast Cancer: Where Do We Stand?

   Breast cancer, the most common cancer occurring worldwide, is characterized by varied clinicopathological features. The current classification based...

   Aviral Kumar, Dey Parama, ... Ajaikumar B. Kunnumakkara in Molecular Biomarkers for Cancer Diagnosis and Therapy

   Chapter 2024
   

9. Emerging immunotherapeutic strategies for the treatment of breast cancer

   Immunotherapy has resulted in unprecedented gains in long-term outcomes for many cancer types and has revolutionized the treatment landscape of solid...

   Laura A. Huppert, Veronica Mariotti, ... Hatem H. Soliman in Breast Cancer Research and Treatment

   Article 30 October 2021

10. Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy

    Regulatory T cells (Tregs) are critical in maintaining immune homeostasis under various pathophysiological conditions. A growing body of evidence...

    H. Ryan Kolb, Nicholas Borcherding, Weizhou Zhang in T Regulatory Cells in Human Health and Diseases

    Chapter 2021
    

11. Immunotherapy in Pancreatic Cancer

    Pancreatic cancer continues to have a dismal prognosis even with the advent of newer systemic therapies. Although immuno-oncology has changed the...

    Zachary P. Yeung, Madappa N. Kundranda in Pancreatic Cancer

    Chapter 2023
    

12. Clinical trials of immunotherapy in triple-negative breast cancer

    Purpose

    Immunotherapy has started to transform the treatment of triple-negative breast cancer (TNBC), in part due to the unique immunogenicity of this...

    Frederick M. Howard, Alexander T. Pearson, Rita Nanda in Breast Cancer Research and Treatment

    Article Open access 14 July 2022

13. Next generation of immune checkpoint inhibitors and beyond

    The immune system is the core defense against cancer development and progression. Failure of the immune system to recognize and eliminate malignant...

    Julian A. Marin-Acevedo, ErinMarie O. Kimbrough, Yanyan Lou in Journal of Hematology & Oncology

    Article Open access 19 March 2021
    

14. Overcoming Cancer Tolerance with Immune Checkpoint Blockade

    Cancer immunotherapy has largely been hindered by the ability of tumors to induce tolerance and escape the immune system. By targeting coinhibitory...

    John W. Myers, George E. Peoples, Guy T. Clifton in Cancer Immunology

    Chapter 2021
    

15. LAG3 blockade coordinates with microwave ablation to promote CD8⁺ T cell-mediated anti-tumor immunity

    Background

    The immune checkpoint inhibitors (ICIs) combined with other therapeutic strategies have shown exciting results in various malignancies, and...

    Dong Shao, Ya** Chen, ... **gting Jiang in Journal of Translational Medicine

    Article Open access 30 September 2022
    

16. New Approaches Targeting Immuno-oncology and Tumor Microenvironment

    Immune checkpoint blockade therapy is now a key tool in the war against cancer. Antibody medications, such as anti-PD-1 and anti-PD-L1, have several...

    Di Zhu, Fenglian He in Cancer Treatment: An Interdisciplinary Approach

    Chapter 2023
    

17. The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

    Purpose of Review

    In this review, we analyzed the current landscape of non-PD-(L)1 targeting immunotherapy.

    Recent Findings

    The advent of...

    Andrea De Giglio, Alessandro Di Federico, ... Francesco Gelsomino in Current Oncology Reports

    Article Open access 27 August 2021
    

18. The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma

    Purpose of Review

    Dual immune checkpoint inhibition with ipilimumab plus nivolumab is currently the most effective, but also by far the most toxic...

    Lea Jessica Albrecht, Elisabeth Livingstone, ... Dirk Schadendorf in Current Oncology Reports

    Article Open access 01 April 2023

19. Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review

    Gynecological malignancies are most leading causes of death among women worldwide. The high prevalence of gynecologic malignancies remains...

    Sandipan Dasgupta, Sakuntala Gayen, ... Souvik Roy in Medical Oncology

    Article 27 March 2024
    

20. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody

    We report the generation of a novel anti-LAG-3/TIGIT bispecific IgG4 antibody, ZGGS15, and evaluated its anti-tumor efficacy in mouse models as...

    Tongcheng Dai, Hao Sun, ... Binhua Lv in Scientific Reports

    Article Open access 09 May 2024